List view / Grid view
It is difficult to treat cancer effectively without causing adverse side effects. In this article, Dr Li, Clinical Assistant Professor at the State University of New York and Board Director of ExonanoRNA, describes how an old strategy that never got off the ground has finally been leveraged to deliver safe,…
The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…
Personalised cancer vaccine increases progression free survival by approximately 50 percent in patients with newly diagnosed glioblastoma.
The new nanoparticle formulation enabled researchers to selectively target glioma cells with Dp44mT, a potent chelator and promising anti-cancer therapeutic, for the first time.
In a Phase Ib trial, pelareorep with GM-CSF, chemoradiotherapy and temozolomide increased progression-free survival by an average of eight months.
Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key…
The researchers found that doses were often missed, with some treatments being scheduled twice a year instead of monthly...
An FDA-approved drug for lymphoma and leukaemia may also help treat the most common - and deadliest type of brain tumour...
Nanoparticles carrying two drugs can cross the blood-brain barrier and shrink glioblastoma tumours...
Addition of hydroxyurea to current chemotherapy significantly improved survival in animal models of glioblastoma...
Research published in The Journal of Experimental Medicine suggests potential treatment for glioblastoma
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
23 June 2016 | By Victoria White, Digital Content Producer
With funding amounting to €3.5 million, the molecule, called 6A10, shall undergo the first phase of clinical testing...
17 June 2013 | By Roche
First approval of Avastin for the treatment of newly diagnosed glioblastoma...
